Dolev Rafaeli

Epitomee Medical shares surged 15% on the Tel Aviv Stock Exchange, exceeding a 110% gain over three days following the appointment of new CEO Dolev Rafaeli. The company aims to revitalize its innovative weight-loss pill through direct-to-consumer digital channels.

Epitomee Medical, having lost 61% of its value over the past year, has appointed Dolev Rafaeli as CEO amidst a crisis. Rafaeli previously led a public company that collapsed, raising questions among investors about whether this is a strategic turnaround or a prelude to a sale.